Delivery Order SPE2DB24D2213-SPE2DB25FGXMS
Award Date 8/14/25
Potential Completion Date 9/5/25
Potential Value $1.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes on August 18, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a biologic medication used primarily in the treatment of allergic asthma and chronic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,440.70 for Xolair 150 mg/ml syringes on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used primarily for treating...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes valued at $1,800.88, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used in the treatment of moderate to severe allergic asthma...
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and other allergic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector prefilled syringes. This competitive award, valued at $3,188.32 with firm fixed pricing, is scheduled for completion by August 18, 2025. The contract represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. As a pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $10,805.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/mL syringes with an ultimate completion date of August 25, 2025. This is an unset-aside, competitively awarded contract that will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xolair is a biologic immunosuppressant used for treating moderate to severe allergic asthma and other allergic conditions, making this a...
- The Defense Logistics Agency awarded a delivery order valued at $3,464.38 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes (2 mL quantity) with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued on August 1, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe asthma and other...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 4, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe allergic asthma and...